7 Questions CTL019 Adcom Should Consider (And 2 It Won’t) – Seeking Alpha
|
7 Questions CTL019 Adcom Should Consider (And 2 It Won’t)
Seeking Alpha Here a single dose of CAR–T cells put 83% of successfully infused subjects into complete remission – a striking finding given that 56% had failed stem cell transplant, and patients overall had progressed after one to eight lines of prior therapy … |
FiercePharma |
Oxford BioMedica and Novartis build on supply deal as CAR–T med nears finish line
FiercePharma Novartis, in explaining its new CAR-T cancer drug candidate, says T cells like this are drawn from a patient’s blood and reprogrammed in the laboratory so that they are genetically coded to hunt the patient’s cancer cells and other B cells expressing a … |
FierceBiotech |
After leaving troubled Arrowhead and RNA, Steven Kanner turns to CRISPR
FierceBiotech Caribou Biosciences has seen biopharma vet and former VP of discovery biology at Arrowhead Steven Kanner join the biotech as the CRISPR R&D race continues apace. Kanner comes on board as CSO and will now lead Caribou’s research into new … Caribou Biosciences Appoints Steven B. Kanner, Ph.D. as Chief Scientific OfficerBusiness Wire (press release) |
FierceBiotech |
After leaving troubled Arrowhead and RNA, Steven Kanner turns to CRISPR
FierceBiotech Caribou Biosciences has seen biopharma vet and former VP of discovery biology at Arrowhead Steven Kanner join the biotech as the CRISPR R&D race continues apace. Kanner comes on board as CSO and will now lead Caribou’s research into new … Caribou Biosciences Appoints Steven B. Kanner, Ph.D. as Chief Scientific OfficerBusiness Wire (press release) |